Comprehensive report on world cancer therapies market

20. November 2009 01:37

Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. [More]

d1ec933e-6b16-4c92-bf1f-1cae23f4af72|0|.0

Posted in: Device / Technology News

Tags: Abraxane, Antibody, Avastin, Bone, Bone Marrow, Cancer, Cell, Chemotherapy, Colorectal Cancer, Diabetes, Drug Delivery, Gemzar, Genetics, Genomics, Hormonal Therapy, Immunization, Immunotherapy, Pfizer, Proteomics, Radiation Therapy, Smoking, Stem Cell, Tarceva, Taxotere, Xeloda

New bone matrix implant offers hope for babies born with skull deformities

19. November 2009 23:43

A synthetic bone matrix offers hope for babies born with craniosynostosis, a condition that causes the plates in the skull to fuse too soon. Implants replacing some of the infant's bone with the biodegradable matrix could eliminate some of the operations currently used to treat the condition. [More]

14d17582-caba-462e-9be3-a85d5ea6b326|0|.0

Posted in: Child Health News | Medical Procedure News | Medical Condition News

Tags: Bone, Bone Marrow, Brain, Implants

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

19. November 2009 03:13

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). [More]

7169822c-90e7-4db1-bb27-26e0162bbe54|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Cough, Cyclophosphamide, Headache, Hepatitis B, Leukemia, Lymphoma, MabThera, Methotrexate, Multiple Sclerosis, Nausea, Rheumatoid Arthritis, Rituximab, Virus

New radical approach to test chemo drugs for potential toxic effects

19. November 2009 02:25

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects. [More]

c84a42b1-b80f-4fe7-93c5-00d675c6b98b|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anemia, Bone, Bone Marrow, Cancer, Chemotherapy, Cyclophosphamide, Docetaxel, Doxorubicin

Minimally invasive procedures drive the global uro-gynecological surgical devices market

18. November 2009 07:50

World uro-gynecological surgical devices market is driven by the growing acceptance of minimally invasive procedures as a convenient alternative option to hysterectomy. [More]

87e83b01-f14d-41fc-8d09-9617c044b246|0|.0

Posted in: Device / Technology News | Women's Health News

Tags: Bone, Bone Marrow, Brain, Cell, Education, Heart Transplantation, Hysterectomy, Implants, Organ Donation, Stem Cell, Transplant

New research report on European orthopedic biomaterial market

18. November 2009 07:29

In 2008, the combined European biomaterial market was worth euro 271.4 million. This includes hyaluronic acid viscosupplements, bone graft substitutes, BMP growth factors, autologous chondrocyte implantation and platelet/bone marrow concentration systems. Within this report, the various bone grafting materials are examined, including autografted bone, allografts, demineralized bone and synthetic bone substitutes. [More]

1d366563-9296-4b55-9a57-dd3f010ed40e|0|.0

Posted in: Device / Technology News

Tags: Bone, Bone Marrow, Orthopedic

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

18. November 2009 04:43

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. [More]

50d53b19-1261-4af8-9034-c4c1c09f6f70|0|.0

Posted in: Medical Procedure News | Medical Condition News

Tags: Avastin, Bevacizumab, Biopsy, Blood Vessel, Bone, Bone Marrow, Brain, Brain Cancer, Brain Tumor, Cancer, Cervical Cancer, Deep Brain Stimulation, Drug Delivery, Education, Gene Therapy, Glioblastoma, Glioblastoma Multiforme, Hospital, Neurology, Oncology, Parkinson's Disease, Penicillin, Pregnancy, Radiology, Spine

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

18. November 2009 04:36

Poniard Pharmaceuticals, Inc. today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). [More]

ebd940d6-5ee0-4981-9f9c-9cbd4c54ac6a|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Bone, Bone Marrow, Cancer, Chemotherapy, Colorectal Cancer, Fluorouracil, Neuropathy, Neutropenia, Oncology, Oxaliplatin, Prostate Cancer, Thrombocytopenia

Phase III randomized clinical trial for Alpharadin to be commenced

18. November 2009 01:30

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide. [More]

a8f6b274-58d5-4b3d-ab5d-62af15d2a053|0|.0

Posted in: Men's Health News | Drug Trial News

Tags: Anemia, Bone, Bone Marrow, Cancer, Life Expectancy, Metastasis, Prostate Cancer, Urology

New encapsulated system may enable doctors to deliver anti-cancer drugs directly to tumors

18. November 2009 01:18

An encapsulation breakthrough by researchers at the Technion-Israel Institute of Technology may enable doctors to deliver anti-cancer drugs directly to tumors over extended periods of time, while preventing the systemic side effects of chemotherapy and other current cancer treatments. [More]

6bfededf-b3ef-439e-8350-d4ff3351a912|0|.0

Posted in: Device / Technology News | Medical Condition News

Tags: Biotechnology, Bone, Bone Marrow, Cancer, Chemotherapy, Education, Glioma, Nanotechnology, Placenta

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

16. November 2009 23:25

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS). [More]

f614074c-9a7c-428a-8ead-cb62f114d384|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Bone, Bone Marrow, Cell, Huntington's Disease, Multiple Sclerosis, Neurology, Neuroscience, Stem Cell, Stroke

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

16. November 2009 10:47

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA. [More]

f3aba2b0-84f6-4e58-a90b-5057d67253a0|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Bone, Bone Marrow, Cancer, Cell, Cell Proliferation, Hematology, Insulin, Kinase Inhibitor, Oncology, Rapamycin

Onyx Pharmaceuticals acquires Proteolix

16. November 2009 10:13

Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. [More]

0fbc4325-e7b3-48da-b125-a399eb516f59|0|.0

Posted in: Business / Finance | Pharmaceutical News

Tags: Bone, Bone Marrow, Cancer, Evolution, Kidney Cancer, Liver Cancer, Multiple Myeloma, Nexavar, Sorafenib

Myeloma UK launches innovative clinical trial network

16. November 2009 08:29

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK. [More]

d79196c0-69a0-4cd3-a17d-377e554c5d49|1|5.0

Posted in: Device / Technology News | Medical Condition News

Tags: Bone, Bone Marrow, Cancer, Hospital, Investment, Multiple Myeloma, Oncology, Rare Disease

Two units of UCB reduce risk of leukemia from returning, shows new study

16. November 2009 01:27

A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. [More]

2c828feb-37c0-4d34-b204-b3fb546c2d10|0|.0